Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: A randomized double-blind study

Atherosclerosis

Volumn 195, Issue 2, 2007, Pages

  Mabuchi, Hiroshi ^a   Nohara, Atsushi ^a   Kobayashi, Junji ^a   Kawashiri, Masa aki ^a   Katsuda, Shoji ^a   Inazu, Akihiro ^a   Koizumi, Junji ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

Adverse effects; Atorvastatin; CoQ10; Hypercholesterolemia; Supplementation

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; GLYCOSYLATED ALBUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYOGLOBIN; PLACEBO; UBIDECARENONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER; MALE; MUSCLE; MUSCLE WEAKNESS; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

AGED; CHOLESTEROL, HDL; CHOLESTEROL, LDL; COENZYMES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; MUSCLES; MYOGLOBIN; PYRROLES; UBIQUINONE; VITAMINS;

EID: 36049005012     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.06.010     Document Type: Article

References (27)

1. Stamler J., Wentworth D., and Neaton J.D. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 256 (1986) 2823-2828
2. Shepherd J., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
3. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;334:1383-9.
4. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. American College of Cardiology; American Heart Association; National Heart, Lung and Blood Institute. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Circulation 2002;106:1024-8.
5. Kontush A., Reich A., Baum K., et al. Plasma ubiquinol-10 is decreased in patients with hyperlipidaemia. Atherosclerosis 129 (1997) 119-126
6. Steinberg D., Parthasarathy S., Carew T.E., Khoo J.C., and Witztum J.L. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med 320 (1989) 915-924
7. Mabuchi H., Higashikata T., Kawashiri M., et al. Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients. J Atheroscler Thromb 12 (2005) 111-119
8. Noji Y., Higashikata T., Inazu A., et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis 163 (2002) 157-164
9. Friedewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18 (1972) 499-502
10. Kotani K., Maekawa M., Kanno T., et al. Distribution of immunoreactive malondialdehyde-modified low-density lipoprotein in human serum. Biochim Biophys Acta 1215 (1994) 121-125
11. Abe F., Yano M., Minami Y., et al. Alterations in fructosamine and glycated albumin levels during childhood. Ann Clin Biochem 26 Pt 4 (1989) 328-331
12. Yamashita S., and Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem 250 (1997) 66-73
13. Langsjoen P.H., and Langsjoen A.M. The clinical use of HMG CoA-reductase inhibitors and the associated depletion of coenzyme Q10, A review of animal and human publications. BioFactors 18 (2003) 101-111
14. Jamal S.M., Eisenberg M.J., and Christopoulos S. Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme. A reductase inhibitors. Am Heart J. 147 (2004) 956-965
15. Okamoto T., Fukui K., Nakamoto M., et al. Serum levels of coenzyme Q10 and lipids in patients during total parenteral nutrition. J Nutr Sci Vitaminol (Tokyo) 32 (1986) 1-12
16. Mabuchi H., Nohara A., Kobayashi J., Kawashiri M., and Inazu A. Coenzyme Q10 reduction with statins: another pleiotropic effect. Curr Drug Ther 2 (2007) 39-51
17. Laaksonen R., Jokelainen K., Sahi T., Tikkanen M.J., and Himberg J.J. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 57 (1995) 62-66
18. Laaksonen R., Jokelainen K., Laakso J., et al. The effect of simvastatin treatment on natural antioxidants in low-density lipoproteins and high-energy phosphates and ubiquinone in skeletal muscle. Am J Cardiol 77 (1996) 851-854
19. Bliznakov E.G. Lipid-lowering drugs (statins), cholesterol, and coenzyme Q10. The Baycol case-modern Pandora's box. Biomed Pharmacother 56 (2002) 56-59
20. Flint O.P., Masters B.A., Gregg R.E., and Durham S.K. Inhibition of cholesterol synthesis by squalene synthase inhibitors does not induce myotoxicity in vitro. Toxicol Appl Pharmacol 145 (1997) 91-98
21. MacDonald J.S., Gerson R.J., Kornbrust D.J., et al. Preclinical evaluation of lovastatin. Am J Cardiol 62 (1988) 16J-27J
22. Singh R.B., Neki N.S., Kartikey K., et al. Effect of coenzyme Q10 on risk of atherosclerosis in patients with recent myocardial infarction. Mol Cell Biochem 246 (2003) 75-82
23. Bargossi A.M., Grossi G., Fiorella P.L., et al. Exogenous CoQ10 supplementation prevents plasma ubiquinone reduction induced by HMG-CoA reductase inhibitors. Mol Aspects Med 15 Suppl: (1994) s187-s193
24. Bleske B.E., Willis R.A., Anthony M., et al. The effect of pravastatin and atorvastatin on coenzyme Q10. Am Heart J 142 (2001) E2
25. Schaefer W.H., Lawrence J.W., Loughlin A.F., et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 194 (2004) 10-23
26. Stocker R., Pollicino C., Gay C.A., et al. Neither plasma coenzyme Q10 concentration, nor its decline during pravastatin therapy, is linked to recurrent cardiovascular disease events: a prospective case-control study from the LIPID study. Atherosclerosis 187 (2006) 198-204
27. Caso G., Kelly P., McNurlan M.A., and Lawson W.E. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. Am J Cardiol 99 (2007) 1409-1412